Scarica l'app Stockscreener
0.34
4.25%
-0.0151
Dopo l'orario di chiusura:
.37
0.03
+8.82%
Precedente Chiudi:
$0.3551
Aprire:
$0.36
Volume 24 ore:
386.02K
Relative Volume:
1.23
Capitalizzazione di mercato:
$24.18M
Reddito:
-
Utile/perdita netta:
$-68.80M
Rapporto P/E:
-0.2906
EPS:
-1.17
Flusso di cassa netto:
$-59.06M
1 W Prestazione:
-10.76%
1M Prestazione:
-20.08%
6M Prestazione:
-47.61%
1 anno Prestazione:
-74.91%
Intervallo 1D:
$0.3307
$0.40
Intervallo di 1 settimana:
$0.3247
$0.42
Portata 52W:
$0.3247
$1.64
Passage Bio Inc Stock (PASG) Company Profile
Nome
Passage Bio Inc
Settore
Industria
Telefono
(267) 866-0312
Indirizzo
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Confronta PASG con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
0.34 | 24.18M | 0 | -68.80M | -59.06M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-29 | Ripresa | Wedbush | Outperform |
| 2024-09-03 | Iniziato | Rodman & Renshaw | Buy |
| 2022-03-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-01-19 | Downgrade | Goldman | Buy → Neutral |
| 2021-07-01 | Iniziato | Raymond James | Outperform |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-03-04 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-02-04 | Iniziato | Guggenheim | Buy |
| 2021-01-25 | Iniziato | Wedbush | Outperform |
| 2021-01-04 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-12-11 | Iniziato | Citigroup | Neutral |
| 2020-08-14 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-06-25 | Downgrade | Goldman | Buy → Neutral |
| 2020-03-25 | Iniziato | Chardan Capital Markets | Buy |
| 2020-03-24 | Iniziato | Cowen | Outperform |
| 2020-03-24 | Iniziato | Goldman | Buy |
| 2020-03-24 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Passage Bio Inc Borsa (PASG) Ultime notizie
Frontotemporal Dementia Pipeline 2025: Key Companies, MOA, - openPR.com
GM1 Gangliosidosis Treatment Market: Advances & Emerging - openPR.com
Fierce Biotech Layoff Tracker 2025: Sail cuts staff; Carisma and Inspirna shutter - Fierce Biotech
Passage Bio stock plunges to 52-week low of $0.35 By Investing.com - Investing.com South Africa
Passage Bio stock plunges to 52-week low of $0.35 - Investing.com
Layoff Tracker: BioAtla Streamlines Operations By Cutting 30% of Staff - BioSpace
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Krabbe Disease Treatment Market is to grow at a 7.22 % CAGR, with the United States leading the market through 2032 - StreetInsider.com
Strategic Partnership To Advance Gene Therapies For Rare Diseases: Key Trend in The GM1 Gangliosidosis Glob... - WhaTech
Annovis Bio Reports Progress in Clinical Trials and Improved Financial Position - MyChesCo
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Third Arc Bio Enters Clinical Stage with First Patient Dosed in ARC101 Study - MyChesCo
Passage Bio stock plunges to 52-week low of $0.38 amid market challenges - Investing.com Australia
Passage Bio stock plunges to 52-week low of $0.38 amid market challenges By Investing.com - Investing.com South Africa
Annovis Bio to Showcase Advancements at Alzheimer’s & Parkinson’s Drug Development Summit - MyChesCo
Passage Bio Reports 2024 Financial Results and Advances in PBFT02 Program - MSN
Wedbush Comments on Passage Bio’s Q1 Earnings (NASDAQ:PASG) - Defense World
Passage Bio (PASG) Upgraded to Buy: Here's What You Should Know - Nasdaq
FY2029 Earnings Forecast for Passage Bio Issued By Wedbush - Defense World
Chardan Cuts Price Target on Passage Bio to $6 From $7, Keeps Buy Rating -March 05, 2025 at 07:36 am EST - Marketscreener.com
Passage Bio (NASDAQ:PASG) Price Target Lowered to $6.00 at Chardan Capital - Defense World
Passage Bio Advances Gene Therapy for Neurodegenerative Diseases - TipRanks
Strategic Restructuring and Promising Data Catalysts Drive Buy Rating for Passage Bio - TipRanks
Chardan cuts Passage Bio stock price target to $6, maintains buy - Investing.com India
Chardan cuts Passage Bio stock price target to $6, maintains buy By Investing.com - Investing.com South Africa
Passage Bio stock plunges to 52-week low of $0.45 - Investing.com India
Passage Bio stock plunges to 52-week low of $0.45 By Investing.com - Investing.com South Africa
Passage Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies - GlobeNewswire Inc.
PASSAGE BIO, INC. Full Year Loss Decreases - Nasdaq
Passage Bio Reports 2024 Financial Results and Program Advances - TipRanks
Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights - The Manila Times
Passage BIO, Inc. SEC 10-K Report - TradingView
Passage Bio reports FY24 EPS ($1.07) vs ($1.86) last year - TipRanks
Passage Bio Reports Fourth Quarter and Full Year 2024 Results -March 04, 2025 at 07:07 am EST - Marketscreener.com
Passage Bio Reports Promising Interim Data for PBFT02 in FTD-GRN Patients and Provides Business Updates - Nasdaq
Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent - The Bakersfield Californian
Can Passage Bio's FTD-GRN Treatment Breakthrough Translate to Market Success? - StockTitan
Passage Bio to Present at Two Major Investor Conferences - MSN
Passage Bio (PASG) to Release Quarterly Earnings on Monday - Defense World
Passage Bio to Participate in Upcoming Investor Conferences - GlobeNewswire
Passage Bio Inc Azioni (PASG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Passage Bio Inc Azioni (PASG) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 10% Owner |
Jan 10 '25 |
Sale |
0.66 |
126,209 |
83,298 |
7,131,636 |
| ORBIMED ADVISORS LLC | 10% Owner |
Jan 14 '25 |
Sale |
0.60 |
79,024 |
47,414 |
7,034,626 |
| ORBIMED ADVISORS LLC | 10% Owner |
Jan 13 '25 |
Sale |
0.64 |
17,986 |
11,511 |
7,113,650 |
| ORBIMED ADVISORS LLC | 10% Owner |
Jan 08 '25 |
Sale |
0.68 |
75,007 |
51,005 |
7,257,845 |
| ORBIMED ADVISORS LLC | 10% Owner |
Jan 07 '25 |
Sale |
0.71 |
52,536 |
37,301 |
7,332,852 |
| ORBIMED ADVISORS LLC | 10% Owner |
Jan 06 '25 |
Sale |
0.77 |
19,481 |
15,000 |
7,385,388 |
10.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):